ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ranibizumab

Also written as “ranibizumab”, “Ranibizumab 0.5 mg” and “rhuFab V2 (ranibizumab)”.

Its studies are mostly in Macular Degeneration · Macular Edema · Choroidal Neovascularization · Retinal Vein Occlusion · Vision Disorders, led by 16 companies.

Drug pageRanibizumab: every studyMany companies study it; this page follows only the 98 they lead. All 351 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 19, 200798 company-led studies, 6 open or runningNext primary completion: Feb 4, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis560 open or runningphase 4since Jul 19, 2007Jan 11, 2006none ahead
Hoffmann-La Rocheits history only244 open or runningphase 4since Jan 13, 2011Mar 24, 2003Feb 4, 2027phase 3 · NCT04657289
AbbVieits history only31 open or runningphase 4since Aug 31, 2011Oct 16, 2008Jul 2031phase 2 · NCT05210803
Samsung Bioepisits history only20 open or runningphase 2since Dec 11, 2023Dec 11, 2023none ahead
Santen Pharmaceuticalits history only20 open or runningphase 2since Oct 1, 2008Oct 1, 2008none ahead
AO GENERIUMits history only11 open or runningphase 3since Nov 30, 2020Nov 30, 2020none ahead
Bioeqits history only10 open or runningphase 3since Nov 19, 2015Nov 19, 2015none ahead
Cynosure Lutronicits history only10 open or runningphase 4since Nov 27, 2018Nov 27, 2018none ahead
Formyconits history only10 open or runningphase 4since Nov 25, 2024Nov 25, 2024none ahead
Incepta Pharmaceuticalsits history only10 open or runningphase 3since Mar 5, 2024Mar 5, 2024none ahead

Also a collaborator on its studies: REGENXBIO, Stada Arzneimittel and MacuSight.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 39 studies since Jan 11, 2006.

  1. Oct 18, 20132 phase 3 studiesNCT01976338, NCT01976312
  2. Nov 12, 2013Phase 4 study in Macular DegenerationNCT01986907 · 1,049 enrolled · Italy
  3. Jan 8, 20142 phase 3 studiesNCT02032173, NCT02034006
  4. Mar 27, 2014Phase 4 study in Macular DegenerationNCT02130024 · 281 enrolled · Australia
  5. Jun 10, 2014Phase 4 study in Macular DegenerationNCT02161575 · 103 enrolled · Germany, United Kingdom
  6. Oct 2, 20142 phase 4 studiesNCT02258009, NCT02257632
  7. Oct 3, 2014Phase 3 study in Vision DisordersNCT02259088 · 384 enrolled · China
  8. Jan 12, 2015Phase 4 study in Diabetic RetinopathyNCT02366468 · 135 enrolled · Germany
  9. Feb 18, 2015Phase 3 study in Retinopathy of PrematurityNCT02375971 · 224 enrolled · United States, Austria, Belgium and more
  10. Jul 30, 2015Phase 4 study in Macular DegenerationNCT02577107 · 12 enrolled · China
  11. Dec 1, 2015Phase 3 study in Retinopathy of PrematurityNCT02640664 · 180 enrolled · United States, Austria, Belgium and more
  12. Dec 16, 2015Phase 4 study in Neovascularization, PathologicNCT02634970
  13. Jul 22, 2016Phase 4 study in Visual Impairment Due to Diabetic Macular EdemaNCT02878681
  14. Apr 23, 2019Phase 2 study in Macular DegenerationNCT03927690 · 91 enrolled · United States, Germany, Puerto Rico and more

TargetBeta

VEGFA →read by rule
“A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule

Other programs on VEGFA

ProgramCompanyFurthest phaseStudies
BevacizumabruleHoffmann-La Rochephase 4250
afliberceptruleRegeneron Pharmaceuticalsphase 489
faricimabruleHoffmann-La Rochephase 417
ivonescimabruleAkesophase 348
pumitamigBioNTechphase 334
tivunatamigPfizerphase 315
suvemcitugruleSimcere Pharmaceutical Groupphase 36
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
surabgene lomparvovecAbbViephase 32
ABBV-1480RemeGenphase 32
HLX37Fosun Pharmaphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24

Studies

All 56 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03927690Macular Degeneration · United States, Germany, Puerto Rico and more2CompletedJun 17, 202291
NCT02878681Visual Impairment Due to Diabetic Macular Edema4WithdrawnSep 20170
NCT02634970Neovascularization, Pathologic4WithdrawnDec 20170
NCT02640664Retinopathy of Prematurity · United States, Austria, Belgium and more3CompletedApr 21, 2022180
NCT02577107Macular Degeneration · China4CompletedJul 9, 201612
NCT02375971Retinopathy of Prematurity · United States, Austria, Belgium and more3CompletedDec 14, 2017224
NCT02366468Diabetic Retinopathy · Germany4CompletedJun 8, 2017135
NCT02259088Vision Disorders · China3CompletedJan 17, 2017384
NCT02258009Visual Impairment Due to Diabetic Macular Edema · Germany4WithdrawnOct 20160
NCT02257632Wet Age-Related Macular Degeneration · Germany4CompletedMar 20, 201741
NCT02161575Macular Degeneration · Germany, United Kingdom4CompletedSep 14, 2017103
NCT02130024Macular Degeneration · Australia4CompletedNov 15, 2017281
NCT02034006Myopia, Degenerative · Italy3CompletedJul 15, 2016200
NCT02032173Macular Edema · France3TerminatedApr 29, 201531
NCT01986907Macular Degeneration · Italy4CompletedJun 15, 20161,049
NCT01972789Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD · Australia4CompletedFeb 28, 2017349
NCT01976338Macular Edema · China, Hong Kong, Indonesia and more3CompletedMar 28, 2016283
NCT01976312Retinal Vein Occlusion · China, Hong Kong, India and more3CompletedMar 14, 2016252
NCT01958918Neovascular Age-related Macular Degeneration · Austria, Belgium, Denmark and more4CompletedNov 22, 2016712
NCT01948830Macular Degeneration · Belgium, Chile, Croatia and more3CompletedNov 19, 2015650
NCT01922102Choroidal Neovascularization · China, Hong Kong, India and more3CompletedSep 14, 2016457
NCT01908816Choroidal Neovascularization · France3CompletedJan 8, 2016270
NCT01846299Macular Edema · Australia, Belgium, Canada and more3CompletedSep 2015181
NCT01840410Choroidal Neovascularization · Australia, Canada, Czech Republic and more3CompletedNov 2015183
NCT01780935Neovascular Age-related Macular Degeneration · Argentina, Austria, Canada and more3CompletedJul 9, 2015671
NCT01775124Macular Degeneration · China4CompletedNov 23, 2015332
NCT01594281Proliferative Diabetic Retinopathy (PDR) · Germany2CompletedNov 30, 2016107
NCT01599650Retinal Vein Occlusion · Australia, Canada, Czech Republic and more3CompletedMay 2015455
NCT01580020Retinal Vein Occlusion · Germany4CompletedOct 2014175
NCT01535261Macular Edema · Australia, Austria, Canada and more3CompletedMar 2015357
NCT01396083Vision Disorders · Germany, Hungary, Poland and more3CompletedJan 2014243
NCT01396057Vision Disorders · Czech Republic, Germany, Hungary and more3CompletedJun 2013244
NCT01377597Retinal Vein Occlusion · Japan3CompletedApr 201247
NCT01315275Vision Disorders · France4CompletedAug 2012394
NCT01297569Macular Edema · Norway4CompletedNov 20127
NCT01257815Diabetic Retinopathy · United Kingdom4CompletedApr 2013111
NCT01217944Myopia, Degenerative · Austria, Canada, France and more3CompletedAug 2012277
NCT01171976Diabetic Macular Edema · Belgium, Czech Republic, France and more3CompletedApr 2013373
NCT01148511Macular Degeneration · Turkey4CompletedApr 201299
NCT01135914Vision Disorders · Canada3CompletedMar 2013241
NCT01131585Visual Impairment Due to Diabetic Macular Edema · Germany3TerminatedJul 2011128
NCT01037348Choroidal Neovascularization · United Kingdom2CompletedMay 201265
NCT00989989Edema · China, Hong Kong, Japan and more3CompletedAug 2011396
NCT00967213Neovascular Age-related Macular Degeneration · Korea, Republic of3CompletedFeb 200810
NCT00942864Macular Edema · Korea, Republic of3CompletedDec 200940
NCT00901186Vision Disorders · Spain2CompletedAug 201283
NCT00826371Macular Degeneration · China3CompletedJul 2010114
NCT00687804Edema · Australia, Belgium, Canada and more3CompletedJan 2010345
NCT00674323Polypoidal Choroidal Vasculopathy · Hong Kong, Korea, Republic of, Singapore and more4CompletedMay 200961
NCT00504959Macular Degeneration · Australia, Belgium, Germany and more4CompletedJan 2010234
NCT00470678Choroidal Neovascularization · Korea, Republic of, Taiwan3CompletedNov 200895
NCT00331864Macular Degeneration · Switzerland3CompletedApr 2008531
NCT00288561Macular Degeneration · Switzerland2Completed
NCT00284089Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD) · Japan2CompletedMar 200788
NCT00284050Diabetic Macular Edema · Switzerland2CompletedJun 2008151
NCT00275821Macular Degeneration · Switzerland3CompletedJan 2008353

How it is read

Names in the registry

  • “Ranibizumab”, 40 entries
  • “ranibizumab”, 18 entries
  • “Ranibizumab 0.5 mg”, 11 entries
  • “rhuFab V2 (ranibizumab)”, 6 entries
  • “Ranibizumab 0.5mg”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.